Archive for August, 2010

The Irish Times—All in our heads: Have we taken psychiatry too far?

Friday, August 13th, 2010

by Jason Walsh

Saturday, August 14th

With drafts of the latest edition of the world’s leading psychiatry manual emerging, critics question the growing medicalisation of life’s problems

OVER THE past three decades, unhappiness has been redefined as depression, shyness has been reclassified as social anxiety disorder – even trivial complaints such as fussy eating are now being viewed through a psychiatric prism. Some of this is due to a single book, the Diagnostic and Statistical Manual , which critics claim is contributing to the ever-expanding empire of mental health. The next official edition of the DSM will be published in May 2013, but draft versions are currently doing the rounds.

Books abound on the creeping medicalisation of everyday life, television shows like In Treatment and The Sopranos revolve around endless therapy sessions, as do films by the likes of Woody Allen. According to clinical psychotherapist Áine Tubridy: “Many people’s problems have sociological causes, not medical ones. They are problems of living. Society needs to recognise that for many people life is bloody hard,” she says.

But there is growing criticism of the DSM itself and the entire model of diagnoses from within the psychiatric establishment.

Consultant psychiatrist Dr Pat Bracken, clinical director of mental health services in west Cork, is unrelenting in his criticism of over-reliance on the DSM .

“Despite being a primarily American book, the DSM is used universally. The alternative is the International Classification of Diseases published by the World Health Organisation,” he says.

“The DSM really took off in the 1980s, introducing what are called ‘operationalised definitions’. That seemed more scientific – a psychiatrist could say: ‘This person fits these diagnostic criteria.’ It introduced a new way of thinking and a focus on diagnosis.”

The criticism boils down to this: reliance on the DSM reduces psychiatry to little more than a consensus on what kind of behaviour or thoughts are abnormal, not an evidence-based analysis of what is wrong in people’s lives.

Bracken says along with the DSM ’s rise there was a corresponding demise in the use of psychotherapy within the medical profession, even if there was an expansion of private use of therapies and counselling, many of which are of dubious efficacy. For Bracken though, the medicalisation of life’s problems creates the worry that “expert” intervention in private life is often disempowering and misses the point.
“The DSM reflects a growing trend to seek ‘experts’ for problems that once wouldn’t have been the domain of the expert: gambling, social anxiety, marriage problems and so on,” says Bracken. “These were once seen as the vicissitudes of life. The demise of organised religion has also contributed to the growing social demand. The DSM legitimises that process and contributes to it,” he says.

This argument links the medical critique of the DSM back to its social implications. The repercussions of privatised social lives driven by the breakup of traditional sources of solidarity outside the family unit – organised religion, trade unions, political parties and other communal organisations – has left individuals confused, lonely and often frightened and encouraged to seek therapy when in fact the problem is a socio-political one.

What, though, is to be done when a patient arrives at their GP’s surgery in despair?

Niall Crumlish, deputy external affairs and policy director of the College of Psychiatry of Ireland, is a locum consultant psychiatrist at St James’s Hospital in Dublin. While he recognises the limitations of psychiatric diagnosis, a patient who asks for help must be given it, he says.

“There are cases for arguing that we are both over-medicalised and under-medicalised,” he says. “There is a huge number of people presenting to primary care providers [seeking psychiatric help] but there are also many not presenting, people with major depression who are functioning but at a much lower level than they might.

“Without the DSM we’d be losing a basic foundation for what we are doing. There is some validity to diagnosis. There is such a thing as a depressive syndrome that you could produce biologically if you were so minded,” he says.

An article published in the Journal of the American Medical Association this July by two of the DSM ’s authors argued the forthcoming fifth edition should be of interest to all health providers, not just psychiatrists.

The DSM is in part a product of the US psychiatric establishment being rocked in the 1960s. David Rosenhan, a follower of the controversial Scottish “anti-psychiatrist” Dr RD Laing, virtually smashed psychoanalysis as it was practised in America almost single handedly.

Rosenhan and some colleagues presented themselves at several mental hospitals claiming to have a sole auditory hallucination – a voice in their heads saying “thud” – and then behaved normally. They were all diagnosed with a variety of mental illnesses: schizophrenia and manic-depressive psychosis. They were eventually released, months later, when they “admitted” they were mentally ill and pretended to get better, demonstrating – they said – that psychiatrists were unable to distinguish between the sane and the insane.

The experiment’s objective wasn’t to prove the obvious point that it is possible to pretend to be mentally ill. Instead it demonstrated that, once admitted, all behaviour by patients is pathologised and ordinary actions were taken as evidence of illness. This rocked the establishment and one hospital challenged Rosenhan to do it again. He agreed and the hospital soon declared it had discovered 41 fakes. Rosenhan then announced he had sent no one for the second experiment.

According to Bracken, this body blow coincided with the increasing use of drug treatment for illnesses: “In the 1950s and 1960s, psychoanalysis was very dominant. Then you had a rejection of that and a move toward the DSM and the psychopharmacology revolution. “Today, the efficacy of the drugs is being called into question,” he says.

By moving away from endless psychoanalysis the diagnostic model favoured by the DSM , particularly from the 1980 third edition onwards, seemed to offer an answer to the problem. Patients symptoms were analysed on a more or less statistical basis and those who fit a specified pattern were declared to have the relevant condition.

Although it has since spread worldwide, the American bias of the DSM is clear: given that unhappiness is not covered by health insurance policies but major depression is, a massive expansion of diagnoses of depression and related illnesses is unsurprising. However, DSM critics argue the book is part of a wider reshaping of our understanding of what it is to be human, not simply a licence to malinger but pathologising everyday experiences.

Read the rest of this article here: http://www.irishtimes.com/newspaper/weekend/2010/0814/1224276782556.html

« Return to news items


Share

US Department of Justice Probes Corruption in Big Pharma; Glaxo, Pfizer, Bristol-Myers Squibb, Eli Lilly & Merck

Friday, August 13th, 2010

Financial Times
By Stephanie Kirchgaessner
August 12, 2010

The US Department of Justice is scrutinising payments by leading pharmaceuticals companies for hospitality, consultants, licensing agreements and charitable donations in markets around the world as part of a wide-ranging corruption probe.

GlaxoSmithKline, Pfizer, Bristol-Myers Squibb and Eli Lilly, among others, have disclosed being contacted by the DoJ and Securities and Exchange Commission in connection with the investigation. Merck, the US drugs group, announced last week that it had also been contacted and was co-operating with investigators.

An industry attorney familiar with the probe said that the DoJ was looking at whether pharma companies had ignored a “systematic risk” inherent in the global drugs business and ignored obligations under local and US anti-bribery law.

The highly regulated nature of the business, combined with the fact that healthcare officials in many non-US markets were government funded, made the industry a natural target for such a probe, the person added.

The investigation is at a relatively early stage but is considered a priority for the DoJ.

While hospitality – including meals and all expenses-paid travel for conferences – has long been considered a potential risk for pharma groups, the DoJ’s probe is looking at all aspects of companies’ dealings in non-US markets, people familiar with the matter say. That includes the recruitment of physicians for clinical trials. In some markets, the same physicians may serve on regulatory boards that approve or deny drugs.

The DoJ declined to comment. But last November, Lanny Breuer, head of the DoJ’s criminal division, announced that investigators would be focusing on international corruption in the pharmaceuticals industry for “years”.

Mr Breuer warned a conference of pharmaceutical industry lawyers that prosecutors were gearing up for an investigation of international corruption in the sector. The drugs companies took notice.

That threat has now become a reality. Merck, AstraZeneca, Eli Lilly, Baxter, SciClone, and Bristol-Myers Squibb have in recent months received inquiries from the DoJ and the Securities and Exchange Commission in connection with an industry-wide bribery ­investigation.

GlaxoSmithKline, the UK drugmaker, told the Financial Times on Thursday that it too had received “inquiries” from US authorities, but that it disclosed the issue “reactively” only to selected reporters in April.

Pfizer, the world’s largest pharmaceutical group, said in February that it had voluntarily provided the DoJ and SEC with information concerning potentially improper payments outside the US and was exploring resolution of the matter.

There is perhaps no industry that is as vulnerable to violations of US anti-bribery laws as the pharmaceutical industry. In markets round the world, the companies deal, sometimes thousands of times in a single day, with doctors, clinicians, hospital operators and regulators who are considered under US law to be government officials, because they are employed by state-owned facilities.

Under the Foreign Corrupt Practices Act, the US anti-bribery law, companies may not offer items of value to foreign government officials for profit. One industry lawyer involved in the matter said global pharmaceutical companies operating in countries with state-run medical institutions deal with government officials at every turn of their business: whether it is seeking the go-ahead for a manufacturing site; obtaining drug licences; conducting clinical trials; importing drugs; selling and marketing drugs to physicians; or getting a product on to a hospital’s approved list.

“What most companies will find is that all of these areas are risky and, if they don’t train and educate their people, they are going to find themselves with issues. For example, if you have hired customs brokers, how do you know they aren’t bribing officials?” the attorney said.

According to the law firm Arnold & Porter, the DoJ is particularly interested in corrupt payments that may have influenced the reliability or integrity of data in clinical trials performed outside the US. A recent report by the Department of Health and Human Services found 80 per cent of marketing applications for drugs approved by the Food and Drug Administration in the US had relied on at least one foreign trial.

“Companies may find themselves facing critical legal issues if approval of products rested on the results of studies the DoJ deems corrupt,” Arnold & Porter said in an advisory letter to clients last month.

A person familiar with the investigation confirmed that clinical trials were one of several areas the DoJ was examining.

Alexandra Wrage, the president of Trace, a non-profit organisation that helps companies establish anti-corruption practices, said that alleged wrong­doing at pharmaceutical companies could often centre on inappropriately lavish hospitality, such as wining and dining doctors from state-run hospitals at conferences in Bali or Monaco.

Read entire article here:  http://www.ft.com/cms/s/0/9a8e8f90-a63e-11df-8767-00144feabdc0.html
(free registration required)

« Return to news items


Share

Overmedication contributes to military suicides, advocates say

Thursday, August 12th, 2010
By Veronica Nett
The Charleston Gazette

CHARLESTON, W.Va. — The suicide rate among military veterans has ballooned in recent years, in part because of overmedication of service members and a lack of support for veterans, advocates for treatment of Post Traumatic Stress Disorder said Thursday.

Psychiatrists sometimes prescribe drugs as a cure without an actual understanding of what the drugs do, said Dr. Peter R. Breggin, a psychiatrist and author from Ithaca, N.Y.

In 2008, the Army’s suicide rate — 20.2 per 100,000 — exceeded the civilian suicide rate for the first time. The civilian suicide rate has held steady for years at about 18 per 100,000, according to the U.S. Department of Defense.

Breggin and seven panelists addressed a crowd of about 50 therapists, social workers, members of the state Veterans Affairs department, in addition to service members and their families at the 2010 PTSD and Traumatic Brain Injury Education and Awareness Conference.

Care-Net, a branch of the state Council of Churches, sponsored the conference at the Blessed John XXIII Pastoral Center in Charleston.

PTSD is the brain’s natural reaction to extreme stress and traumatizing experiences, said Breggin, the conference’s keynote speaker. Tramuatic brain injury looks just like PTSD, he said.

“There is no drug that improves the function of the brain,” said Breggin, who said he will not prescribe psychiatric drugs as treatment for any disorder.

Psychiatric drugs, such as antidepressants and anxiety medication, alter the chemical balance in the brain, disrupt the release of serotonin and, in many cases, have the same effect as street drugs, Breggin said.

Patients using psychiatric drugs have experienced psychotic and violent behavior, attempted suicide and are unable to think clearly, Breggin said.

Mary Lahas talked about her son, Michael, who she said stuck IV needles into his arms in a suicide attempt.

Her son, an Army infantry member, survived roadside bomb explosions, and witnessed the shooting death of civilians in Iraq, Lahas said Thursday.

He returned from his first deployment in 2008 with PTSD and TBI and suffered from headaches, anxiety, guilt, tinnitus and memory problems, Lahas said. He refused to seek help, she said, because he saw other soldiers ridiculed who did.

When he finally did seek help, he was given a “cocktail of death,” that included antidepressants, anxiety medications and sleep aids, Lahas said.

“He was so overmedicated he could not care for himself — eat, sleep or brush his teeth,” she said.

The drugs and stress led him to try to take his own life, and while standing in his bathroom bleeding, he drew a smiley face on the wall in his own blood, she said.

Read the rest of this article here: http://wvgazette.com/News/201008120975

« Return to news items


Share

WW market for antipsychotics to reach $20.8 bil—hence the heavy PR/marketing of ‘schizophrenia’—its a lucrative market

Thursday, August 12th, 2010

PR Newswire
August 10, 2010

Reportlinker.com announces that a new market research report is available in its catalogue:

Antipsychotic Drugs: Technologies and Global Markets

The total worldwide market for antipsychotic drugs is expected to reach $19.6 billion in 2010.  With continued market penetration into new diseases and price increases for currently marketed antipsychotics, this market is expected to grow to a high of $20.8 billion in 2011 and then hit a low of $14.4 billion in 2013, before resuming growth again to $14.8 billion in worldwide sales for 2014. This represents a total compound annual growth rate (CAGR) of -4.6%.

Most atypical antipsychotics will lose patent exclusivity through the study period, resulting in a compound annual growth rate (CAGR) of -3.7%. This market will be worth an estimated $18.5 billion by the end of 2010, but decrease to $14.5 billion in 2014.

Read entire article here:  http://www.prnewswire.com/news-releases/reportlinker-adds-antipsychotic-drugs-technologies-and-global-markets-100343619.html

« Return to news items


Share

The Hidden Tragedy of the CIA’s Experiments on Children

Wednesday, August 11th, 2010

Truthout
By H.P. Albarelli Jr. and Dr. Jeffrey S. Kaye
August 11, 2010

Bobby is seven years old, but this is not the first time he has been subjected to electroshock. It’s his third time. In all, over the next year, Bobby will experience eight electroshock sessions. Placed on the examining table, he is held down by two male attendants while the physician places a solution on his temples. Bobby struggles with the two men holding him down, but his efforts are useless. He cries out and tries to pull away. One of the attendants tries to force a thick wedge of rubber into his mouth. He turns his head sharply away and cries out, “Let me go, please. I don’t want to be here. Please, let me go.” Bobby’s physician looks irritated and she tells him, “Come on now, Bobby, try to act like a big boy and be still and relax.” Bobby turns his head away from the woman and opens his mouth for the wedge that will prevent him from biting through his tongue. He begins to cry silently, his small shoulders shaking and he stiffens his body against what he knows is coming.

CIA Mind Control Doctors
To find out more about psychiatry/
government experiments, watch this
interview with Psychiatrist and Author,
Colin Ross

Mary is only five years old. She sits on a small, straight-backed chair, moving her legs back and forth, humming the same four notes over and over and over. Her head, framed in a tangled mass of golden curls, moves up and down with each note. For the first three years of her life, Mary was thought to be a mostly normal child. Then, after she began behaving oddly, she had been handed off to a foster family. Her father and mother didn’t want her any longer. She had become too strange for her father, whose alcoholism clouded any awareness of his young daughter. Mary’s mother had never wanted her anyway and was happy to have her placed in another home. When the LSD Mary has been given begins to have its effects, she stops moving her head and legs and sits staring at the wall. She doesn’t move at all. After about ten minutes, she looks at the nearby physician observing her, and says, “God isn’t coming back today. He’s too busy. He won’t be back here for weeks.”

From early 1940 to 1953, Dr. Lauretta Bender, a highly respected child neuropsychiatrist practicing at Bellevue Hospital in New York City, experimented extensively with electroshock therapy on children who had been diagnosed with “autistic schizophrenia.” In all, it has been reported that Bender administered electroconvulsive therapy to at least 100 children ranging in age from three years old to 12 years, with some reports indicating the total may be twice that number. One source reports that, inclusive of Bender’s work, electroconvulsive treatment was used on more than 500 children at Bellevue Hospital from 1942 to 1956, and then at Creedmoor State Hospital Children’s Service from 1956 to 1969. Bender was a confident and dogmatic woman, who bristled at criticism, oftentimes refused to acknowledge reality even when it stood starkly before her.

Despite publicly claiming good results with electroshock treatment, privately Bender said she was seriously disappointed in the aftereffects and results shown by the subject children. Indeed, the condition of some of the children appeared to have only worsened. One six-year-old boy, after being shocked several times, went from being a shy, withdrawn child to acting increasingly aggressive and violent. Another child, a seven-year-old girl, following five electroshock sessions had become nearly catatonic.

Years later, another of Bender’s young patients who became overly aggressive after about 20 treatments, now grown, was convicted in court as a “multiple murderer.” Others, in adulthood, reportedly were in and of trouble and prison for a battery of petty and violent crimes. A 1954 scientific study of about 50 of Bender’s young electroshock patients, conducted by two psychologists, found that nearly all were worse off after the “therapy” and that some had become suicidal after treatment. One of the children studied in 1954 was the son of well-known writer Jacqueline Susann, author of the bestselling novel “Valley of the Dolls.” Susann’s son, Guy, was diagnosed with autism shortly after birth and, when he was three years old, Dr. Bender convinced Susann and her husband that Guy could be successfully treated with electroshock therapy. Guy returned home from Bender’s care a nearly lifeless child. Susann later told people that Bender had “destroyed” her son. Guy has been confined to institutions since his treatment.

To their credit, some of Dr. Bender’s colleagues considered her use of electroshock on children “scandalous,” but few colleagues spoke out against her, a situation still today common among those in the medical profession. Said Dr. Leon Eisenberg, a widely respected physician and true pioneer in the study of autistic children, “[Lauretta Bender] claimed that some of these children recovered [because of her use of shock treatment]. I once wrote a paper in which I referred to several studies by [Dr. E. R.] Clardy. He was at Rockwin State Hospital – the back up to Bellevue – and he described the arrival of these children. He considered them psychotic and perhaps worse off then before the treatment.” (This writer could find no case where any of Bender’s colleagues spoke out against her decidedly racist viewpoints. Bender made it quite clear that she felt that African-Americans were best characterized by their “capacity for laziness” and “ability to dance,” both features, Bender claimed, of the “specific brain impulses” of African-Americans.)

About the same time Dr. Bender was conducting her electroshock experiments, she was also widely experimenting on autistic and schizophrenic children with what she termed other “treatment endeavors.” These included use of a wide array of psycho-pharmaceutical agents, several provided to her by the Sandoz Chemical Co. in Basel, Switzerland, as well as Metrazol, sub-shock insulin therapy, amphetamines and anticonvulsants. Metrazol was a trade name for pentylenetetrazol, a drug used as a circulatory and respiratory stimulant. High doses cause convulsions, as discovered in 1934 by the Hungarian-American neurologist and psychiatrist Ladislas J. Meduna.

Read entire article here:  http://www.truth-out.org/the-hidden-tragedy-cias-experiments-children62208

« Return to news items


Share

Following 7-year-old’s psychiatric drug-induced suicide—Florida bans foster children from clinical drug trials

Wednesday, August 11th, 2010

Education News
By Pareesha Narang
August 9, 2010

Sixteen months after 7-year-old Gabriel Myers committed suicide while taking psychotropic drugs, the state of Florida has banned allowing any children in the state’s custody from participating in clinical drug trials.

It is unclear if Gabriel was involved in any clinical trials. The doctor who prescribed the medicines to him was conducting clinical trials involving psychotropic drops and the Food and Drug Administration sent him a warning letter earlier this year about overdosing children who were involved in those trials.

The Florida ban was imposed  after the state tried to find out from the FDA if Gabriel or any other foster care child in Florida was a participant in such trials, and the FDA said it could not disclose such information and that mostly they know participants by only coded identifiers.

Though Florida officials had suggested that, under such circumstances, the Federal Food and Drug Administration ban all foster care children from participating in such trials, the agency refused, saying the children might benefit from the drugs.

In a letter last month,  George Sheldon, secretary of the state’s Department of Children and Families (DCF), announced that regardless of the FDA’s stance the state, using “administrative procedures,” was precluding children in state care from participating in such trials.

“Children who come into our care are often the victims of abuse, neglect, and abandonment,” Sheldon said in the letter. “It is therefore imperative that the state do all in its power to stabilize their environment, to protect them from further trauma, and to foster their successful growth into adulthood.”…

Before he hanged himself in his foster home, Gabriel had been taking different drugs for a variety of psychological problems – and some of the drugs were not approved for use in children.  Some of these drugs, including Lexapro, Vyvanse and Symbyax, had “black box” warnings cautioning dangerous side effects such as suicidal thoughts.

Read entire article here:  http://www.educationnews.org/educationnewstoday/97911.html

« Return to news items


Share

Australian of the Year Psychiatrist Patrick McGorry. a.k.a. The Spin Doctor

Monday, August 9th, 2010

Note:  Should there be any doubt of how highly controversial and dangerous Patrick McGorry’s pre-diagnosing, pre-drugging agenda actually is,  consider that even the former task force chairman of the American Psychiatric Association’s  Diagnostic and Statistical Manual of Mental disorders (DSM),  has had articles featured in Psychology Today calling “Psychosis Risk” syndrome “dangerous and stigmatizing” and that it will inevitably lead to children being needlessly drugged with psychiatry’s  most powerful psychotropics, antipsychotic drugs.  When even fellow psychiatrists start slamming proposed “mental disorders” at this level,  it is evident that McGorry’s agenda is far more dangerous than anything previously witnessed. http://www.cchrint.org/2010/07/30/austrailan-psychiatrist-patrick-mcgorrys-global-agenda-takes-a-hit-from-former-dsm-task-force-member-psychiatrist-allen-frances/

OnlineOpinion.com

By Melissa Raven and Jon Jureidini
August 9, 2010

Since Professor Patrick McGorry was appointed 2010 Australian of the Year, mental health has had a remarkably prominent public profile.

GetUp has played a major role, with a campaign promoting McGorry’s call for radical reform, particularly in relation to youth mental health, arguing that early intervention should be the norm. Many Australians have enthusiastically responded, donating money, signing a petition, and sending faxes to politicians.

A further impetus came when Adjunct Professor John Mendoza dramatically resigned as Chair of the National Advisory Council on Mental Health (or, as he terms it, “head advisor to the Rudd Government on mental health”) and joined the GetUp campaign. Mendoza endorses many of McGorry’s demands, including a national rollout of headspace youth mental health centres and the Early Psychosis Prevention and Intervention Centre (EPPIC).

McGorry and Mendoza are adept at capturing media attention, using emotive statistics and feel-good messages as powerful soundbites. However, few people seem to have critically examined their claims, which have been widely accepted at face value.

We have examined several claims, and found them seriously problematic. Not only is there a high degree of spin in the rhetoric but also there is misrepresentation of evidence.

Two claims are analysed here. In each case the evidence cited to justify the claim, although relevant, does not support it, and other evidence challenges the validity of the claim.

Claim: One third of Australian suicide cases had been discharged inappropriately

According to Mendoza, more than a third of Australians who kill themselves had been discharged too early or without care from hospitals. This claim has been publicised by GetUp on its website and in emails from Mendoza about his resignation distributed to GetUp members.

Mendoza has confirmed to one of us (JJ) that the basis is the 2007 New South Wales Tracking Tragedy report. The introduction of that report does refer to “a third of suicides”:

Other systematic reviews of suicide and previous work of this Committee suggest that around a third of suicides may realistically have been preventible [sic] with more optimal care.

However, the report does not support Mendoza’s claim, because it focuses specifically on 113 cases of suicide by people receiving treatment for depression in community mental health settings, not on suicides in the general population. It is tragic that approximately 38 suicides might have been prevented, but this number is hundreds less than one-third of the 1,776 suicides in the NSW population in that period (2003-2005 inclusive). Furthermore, only 14 (12 per cent) of the 113 people had been discharged (figure 1, p34), appropriately or otherwise.

An earlier Tracking Tragedy report revealed there were about 20 suicides annually in NSW within 28 days of discharge. It concluded that “Suicide death on discharge from hospital is a rare event”.

In the period covered in that report (1999-2003), there were approximately 750 suicides annually in NSW. The 20-odd people discharged within 28 days prior to suicide annually constituted only 2.7 per cent of them. Even if all those discharges were inappropriate, Mendoza’s claim would be wrong by a factor of more than ten. However, the report concluded that only “Between one-quarter and one-third of suicide deaths following discharge from hospital could reasonably be prevented”. Taking the higher of those estimates gives approximately 7 out of 750 (less than 1 per cent), making Mendoza’s claim more than 30-fold wrong.

The “other systematic review” cited in the 2007 Tracking Tragedy report is the 2006 report of the National Confidential Inquiry into Suicide and Homicide by People with Mental Illness (in England and Wales). This does not support Mendoza’s claim. Only 27 per cent of suicides had followed any current or recent contact with the mental health system. Twenty per cent of suicides among these patients occurred within three months of discharge (5.4 per cent of total suicides), but only 18-22 per cent of these were judged preventable, representing only about 1 per cent of all suicides in England and Wales.

Unquestionably there is a need to improve discharge planning and follow-up – for many reasons, not just because of the risk of suicide. However, this is not relevant to the majority of suicide cases.

Mendoza has had the unwitting assistance of GetUp in misleading the Australian public. However, when one of us (JJ) explained why Mendoza’s claim is incorrect, GetUp’s response was “we’ll adjust our future communications accordingly”, but inexplicably it “won’t however be removing anything from the website or issuing any correction statements”. GetUp focuses on “giving everyday Australians opportunities to get involved and hold politicians accountable, on important issues”, yet it is unwilling to be held accountable for misleading everyday Australians about mental health, and its website carries information it knows to be incorrect.

Claim: 750,000 young Australians are denied desperately needed mental health services

McGorry has repeatedly claimed there is a hidden waiting-list of 750,000 young Australians who are denied access to much-needed mental health services. His website refers to “the waiting list of 750,000 young Australians currently locked out of the mental health care they and their families desperately need”.

In his submission to the Senate inquiry into COAG health reforms, McGorry explicitly linked the unmet need to insufficient funding for headspace and EPPIC. He made similar claims at a hearing (PDF 442KB). The Senate report (PDF 1.32MB) quoted his testimony uncritically. Others have also echoed his claim uncritically, including Lesley Russell (PDF 93KB) from the Menzies Centre for Health Policy. Furthermore, McGorry’s claim has been implicitly endorsed by the Coalition’s Real Action Plan for Better Mental Health.

McGorry’s 750,000 claim is based on the 2007 National Survey of Mental Health and Wellbeing (NSMHW), which found that 671,000 (26 per cent) 16-24-year-olds experienced a mental disorder in the previous year, and only 23 per cent of them accessed treatment. McGorry’s 750,000 figure, encompassing 12-25-year-olds, the focus of headspace, seems a reasonable estimate of people in that age range with untreated disorders.

However, diagnosis, particularly in surveys, is not the same as treatment need, contrary to the usual interpretation. According to Scott Henderson (an architect of the original NSMHW) and colleagues:

having symptoms, even at case level, is necessary but not sufficient to justify treatment … it is irrational to suggest that one in five adults need treatment for a case-level mental disorder. (p204)

Leading US psychiatric epidemiologists have similarly argued that prevalence rates in surveys do not represent treatment need. Robert Spitzer, a key player in the development of the DSM (Diagnostic and Statistical Manual of Mental Disorder), published a paper with the title: “Diagnosis and need for treatment are not the same”. The main reason is that many cases are not particularly serious. According to Darrel Regier (Vice-Chair of the DSM-V Task Force) and colleagues: “most episodes of mental illness are neither severe nor long-lasting”.

There is a strong bias towards treatment of people who most need it. In the NSMHW, only 17 per cent of young people with disorders (PDF 308KB) had severe disorders, 35 per cent moderate, and 48 per cent mild. Furthermore, 51 per cent of young people with severe disorders accessed treatment. And according to Gavin Andrews (another key player in the NSMHW), many cases of mental disorders are transient but the extent of remission is usually underestimated.

The gap between prevalence and help-seeking in young people is largely due to high rates of substance use disorders (particularly mild cases of harmful alcohol use) with low rates of help-seeking (particularly by young men). The relatively low threshold for diagnosis of harmful alcohol use – which has a high rate of spontaneous remission – inflates the prevalence of mental disorders. This was recently discussed in some detail by one of us (MR).

Undoubtedly some untreated young people would benefit from treatment. However, for many of them, GP services would be more appropriate than specialist services like headspace or EPPIC. Indeed, according to Andrews and colleagues, “in Australia as elsewhere, the GP is the key to treatment for most people with mental disorders”.

So most of the 750,000 are not locked out of treatment, and most do not desperately need it. Most choose not to access treatment, and often that choice is appropriate, because the disorders are mild and transient. 750,000 is a gross over-estimate of treatment need, particularly need for specialist services like headspace and EPPIC.

Conclusion

These are only two of a number of inaccurate claims made by McGorry and Mendoza that inflate the scale of problems in the mental health system and exaggerate the benefits of their brand of solution – central to which is massively increased funding for headspace and EPPIC – which they imply is the only alternative to the status quo.

But does it really matter if some of the claims made by high-profile mental health advocates are inaccurate? The system is in crisis, and radical change is needed. McGorry’s plan, resoundingly seconded by Mendoza and many mental health community groups, has the support of the public and politicians, so shouldn’t we capitalise on the momentum?

That is how many people will respond to our critical analysis of these claims. It is essentially how GetUp has responded.

However, we believe it does matter that people have been misled to believe that more than a third of people who kill themselves have been inappropriately discharged from hospital, because this implies that massive resources should be directed towards psychiatric inpatients, who constitute only a small proportion of people at risk of suicide, and it deflects attention from other at-risk groups such as unemployed and elderly men. Such resourcing would have inevitable opportunity costs in terms of funding of other services.

We believe it does matter that people have been misled to believe there is a huge hidden waiting-list of young Australians desperately in need of mental health treatment, because this implies that even more resources should be directed towards a relatively narrow age-band. It matters even more that it is claimed that the treatment required is headspace/EPPIC treatment, and the claim is used to justify demands for greatly increased funding for those services, which would increase the opportunity costs.

We also believe it matters that the important role of GPs in mental health treatment is being ignored and implicitly denigrated. This is likely to lead to further deskilling and under-resourcing of GPs, reducing their capacity to intervene effectively with young people, many of whom have mild and relatively short-term mental health problems.

We are not entirely alone in criticising McGorry’s campaign for mental health reform centred on specialist early intervention in youth mental health. The Royal Australian and New Zealand College of Psychiatrists’ submission (PDF 157KB) to the National Health and Hospitals Reform Commission expressed concern about “investment in age specific community based services that have neither identified transition points nor evidence to support that age specific services provide better outcomes” and cautioned that “there are no simple solutions to reforming the mental health sector”. However, this seems to have been ignored by the NHHRC: its report (which will profoundly influence Australian health policy for decades) endorsed McGorry’s demand for a national rollout of EPPIC and favourably mentioned headspace.

On a different level, we also believe it matters that high-profile mental health advocates are able to mislead by proclaiming authoritative-sounding statistics that almost no one bothers to check, and that misleading claims are incorporated into health policy. This uncritical acceptance is an impediment to evidence-based policy. Worse, when the inaccuracies of claims are pointed out, there is often reluctance to acknowledge the misinformation and attempt to rectify it, as is the case with GetUp.

Read the rest of this article here:  http://www.onlineopinion.com.au/view.asp?article=10793&page=0

« Return to news items


Share

Australian of the Year Psychiatrist Patrick McGorry accused of misleading public to secure his pre-drugging kids agenda

Monday, August 9th, 2010

For more information about Patrick McGorry’s global agenda, click here: http://www.cchrint.org/2010/06/16/australian-psychiatrist-patrick-mcgorry-wants-his-pre-drugging-agenda-to-go-global/

The Sydney Morning Herald
By Julia Medew
August 9, 2010

LEADING mental health reform figures, including Australian of the Year Patrick McGorry, are misleading the public with dodgy statistics that suit their causes, a prominent psychiatrist says.

Adelaide University Associate Professor Jon Jureidini claimed yesterday that Professor McGorry and National Advisory Council on Mental Health former chairman John Mendoza had exaggerated or misrepresented mental healthcare statistics during the reform debate.

But Professor McGorry and associate professor Mendoza have denied misleading anyone.

Associate Professor Jureidini said Professor McGorry – a world-renowned psychiatrist whose youth-targeted services recently won bipartisan support – had falsely claimed that 750,000 young Australians were ”locked out” of care they ”desperately” needed.

”He’s taken the biggest possible figure you can come up with for people who might have any level of distress or unhappiness, which of course needs to be taken seriously and responded to, but he’s assuming they all require … a mental health intervention,” said Associate Professor Jureidini, who specialises in child psychiatry.

”It’s the way politicians operate. You look at figures and put a spin on it that suits your point of view. I don’t think that has a place in scientific conversations about the need for health interventions.”

Associate Professor Jureidini said although surveys showed about 750,000 young people experienced an untreated mental disorder at some stage every year, many would have mild and transient disorders that did not need treatment.

He also accused Associate Professor Mendoza of incorrectly asserting that more than a third of suicides in Australia involved people inappropriately discharged from hospitals.

He said a more accurate figure was about 1 per cent.

”Nobody would argue with people bringing forward data to support their arguments, but it needs to be done responsibly and accurately, not in a way that exaggerates it,” he said.

Read entire article here:  http://www.smh.com.au/national/mcgorry-misleading-the-public-20100808-11qes.html

« Return to news items


Share

So much for psychiatry’s claim mental disorders are ‘medical conditions’—they’re now diagnosing patients by video uploads

Friday, August 6th, 2010

We would like to point out something quite obvious regarding this latest psychiatric evaluation tool;  Psychiatrists are forever claiming that mental “disorders” are on par with real physical illness—That ADHD, Bipolar Disorder,  Obsessive Compulsive disorder and the myriad of DSM diagnoses are the same as real medical conditions like cancer or diabetes.  Well,  try and imagine a doctor diagnosing a patient with cancer via a videotaped interview.  Or diabetes.     Yet the “mental illness is the same as physical illness” is the PR line used by psycho/pharma to obtain billions in government funding.     And that’s why mandating mental health parity (equal insurance coverage for mental disorders as that which is covered for real physical illness/disease)  is a joke.  Its not about parity for people with “mental illness” its about a blank check for Psycho/Pharma to bill insurance.

PhysOrg.com
August 6, 2010

Psychiatrists can accurately assess a patient’s mental health by viewing videotaped interviews that are sent to them for consultation and treatment recommendations, according to a new study by researchers at the UC Davis School of Medicine.

The approach, called asynchronous telepsychiatry, uses store-and-forward technology, in which medical information is retrieved, stored and transmitted for later review using e-mail or Web applications. It has been used extensively for specialties like dermatology, with photos of skin conditions sent to dermatologists, or x-rays sent to radiologists for assessment.

However, the current study is the first to examine store-and-forward technology for psychiatry, said Peter Yellowlees, professor of psychiatry and behavioral sciences and the study’s lead author. “A Feasibility Study of the Use of Asynchronous Telepsychiatry for Psychiatric Consultations” is published in the August issue of the journal Psychiatric Services.

“We’ve demonstrated that this approach is feasible and very efficient,” said Yellowlees, who is an internationally recognized expert in telepsychiatry. “Using store-and-forward technology allows us to provide opinions to primary-care doctors much more quickly than would usually be the case.”

The researchers conducted the study to determine the effectiveness of asynchronous telepsychiatry for patients in Tulare County, a rural county in California’s San Joaquin Valley. Sixty male and female patients between the ages of 27 and 64 who had mostly mild-to-moderate mental-health disorders were included in the study.

Researcher Alberto Odor, associate adjunct professor of anesthesiology and , conducted 20- to 30-minute structured videotaped interviews at a community-based primary-care clinic. The videos were then uploaded to UC Davis’ specially designed Web-based telepsychiatry consultation record. Yellowlees and Donald Hilty, professor of psychiatry and behavioral sciences, reviewed the videotapes and provided psychiatric evaluations to the patients’ community-based primary-care physicians.

Fifty-one percent of patients received diagnoses of mood disorders, 19 percent received diagnoses of substance use disorders, 32 percent received diagnoses of anxiety disorders and 5 percent received other diagnoses — including kleptomania, schizophrenia and parasomnia. Five patients also were diagnosed with disorders such as borderline personality disorder, obsessive-compulsive disorder or personality disorder. Some of the individuals had multiple diagnoses.

Read entire article:  http://www.physorg.com/news200305373.html

Psychiatrists can accurately assess a patient’s mental health by viewing videotaped interviews that are sent to them for consultation and treatment recommendations, according to a new study by researchers at the UC Davis School of Medicine.

« Return to news items


Share

OpEdNews.com—The Mothers Act: How Pharmaceutical’s Control Puts New Mothers & Infants in Grave Danger

Thursday, August 5th, 2010

Note: To see side effects of psychiatric drugs on pregnant women that have been reported to the US FDA,  click on this link http://www.cchrint.org/psychdrugdangers/medwatch_psych_drug_adverse_reactions.php scroll all the way down in the Drug Class/Drug Name drop down link and select ANTIDEPRESSANTS, then in the AGE RANGE category, select  age range of 0-1 years.

OpEdNews
By K. L. Carlson
August 5, 2010

Mom’s Opportunity to Access Health, Education, Research, and Support for Postpartum Depression Act sounds very supportive of new mothers. The truth is just the opposite. The cleverly worded title can be shortened to the Mothers Act and it was written by and for the pharmaceutical industry. It was introduced by Senator Robert Menendez of New Jersey; the state with the most pharmaceutical companies’ headquarters. According to the public interest group, Common Cause, Senator Menendez received over $2 million from the healthcare industry, including drug companies.

The Mothers Act was included in the immense health plan that was recently signed into law. New mothers need to be made aware that this Act was not written to benefit them, but to benefit the drug companies. This Act will have grave results literally.

Postpartum depression, as defined in the Act, is a “mood disorder” that has three categories. The most severe category is “postpartum psychosis.” Notice the use of psychiatric terms. The public is supposed to believe that motherhood can cause mental illness. Fear of a new mother suffering “postpartum psychosis” is then increased by the Act stating that one in every one thousand new mothers will suffer the mental illness.

The Act states that postpartum depression goes undiagnosed and untreated due to “social stigma surrounding depression and mental illness.” So giving birth and becoming a new mother with vastly fluctuating hormones and physiological changes, as well as the demands of a new baby, is now a mental illness. What is the probability the Mothers Act would have been written if psychiatric drugs did not reap more than $330 billion dollars a year?

The Act establishes federally funded grants to screen all new mothers before they leave their birthing centers and to continue screening during the first year. Although it is unknown why some women suffer depression after giving birth, and most likely there are many reasons including concerns of financially supporting a new baby, the pharmaceutical industry has ensured that it is considered a mental illness that will lead to non-curing, addictive, dangerous psychiatric drugs. As stated in the Act, “the new mother shall be referred to an appropriate mental healthcare provider.”

“There is no evidence that any mental disorder is caused by chemical imbalance,” a Surgeon General’s report states. The much-touted idea of brain chemical imbalance is a total myth with no scientific research ever supporting it. All psychiatric “disorders” are voted into existence by the American Psychiatric Association and have no objective diagnostic tests, such as blood tests or hormone tests. The Mothers Act is the latest version of the old story of the Emperor’s New Clothes – get people to believe something exists when in fact it does not. Mothers who have trouble emotionally after giving birth do not have any mental illness. They may have temporary hormonal imbalance. They may need a stronger emotional support system to feel confident they can get help with the new baby. They may need financial assistance. But they are not mentally ill.

The Act also funds clinical research “for the development and evaluation of new treatments for postpartum conditions, including new biological agents.” That means synthetic drugs. The pharmaceutical industry has ensured more tax dollars will continue to flow into its coffers.

“The suicide rate is 718 for every 100,000 people taking SSRI/SNRI drugs in clinical trials,” Dr. Arif Khan told NIH in August 2002. SSRI/SNRI drugs are antidepressant drugs, which is an oxymoron because the drugs cause depression. They should be called pro-depression drugs. The suicide rate in the general population not taking psychiatric drugs is about 11 for every 100,000 people. In fact, all 33 brands of SSRI/SNRI drugs carry the FDA’s most severe warning, a Black Box Warning, for suicide. Besides suicide the drugs have more than 100 other severe side effects, including anxiety, panic attacks, irritability, hallucinations, hostility, aggressiveness, and mania. Antidepressants are mind-altering drugs that have never been shown in any clinical study to help depressed people much more than the herb St. John’s Wort or the placebo (sugar pill). In one study the placebo group had significantly better results than the group receiving the antidepressant drug, confirming that the body has natural ways to deal with the ups and downs of life.

Once people are labeled with a mental disorder, such as postpartum psychosis, their behavior is then blamed on the disorder when in fact the drugs are causing the behavior. For a real life example, check out Amy Philo’s story on You Tube. She was anxious because her newborn son had a severe allergic reaction to a formula given to her by a physician. Amy’s fear and anxiety for her child was absolutely normal and would have subsided once she had her baby safely at home. Instead, she was diagnosed as suffering from postpartum depression and given an antidepressant. She asked if the drug would be safe for her baby since she was breast-feeding. A physician told her yes, the drug would make her baby happy too. Research results do not support what the doctor told Amy. “In conclusion, our results suggest that maternal exposure to fluoxetine (Prozac, Luvox, Sarafem, and Symbyax) during pregnancy and lactation results in enduring behavioral alterations “throughout life.” All psychiatric drugs, including antidepressants, are neurotoxins. That means they kill nerve cells everywhere in the body.

“After only being on the antidepressant for a couple of days I had thoughts of killing my baby.” Amy was horrified, but instead of blaming the drug’s known side effects, the physician blamed the label of postpartum depression. Obviously, Amy’s “mental illness” had worsened and she now needed to be put in a psychiatric ward. She didn’t agree to the incarceration but her resistance was again labeled as due to her mental illness. The white coats know best! Fortunately Amy’s story has a happy ending. She suspected the antidepressant was causing her strange thought patterns. She managed to be released from the psychiatric ward after only a brief stay and she stopped taking the drugs they had given her. All of Amy’s symptoms that had been labeled by the medical community as postpartum depression symptoms ceased when she stopped taking the drugs. Her baby and she were home together. A happy ending. That will not be the case when they initiate the Mothers Act. Since every mother is potential income to psychiatry and the pharmaceutical industry, we can predict that the majority of new mothers will be labeled and drugged for postpartum depression. It is about money, not health.

The pharmaceutical industry and psychiatry are conjoined twins joined at the wallet. “Adoption of the Mothers Act is a positive development for women and their families,” says Alan F. Schatzberg, MD, President of the American Psychiatric Association (APA). Scharzberg was one of several influential psychiatrists who Senator Grassley’s investigations found had failed to disclose financial ties to pharmaceutical companies.

“In order to survive we psychiatrists must go where the money is,” Dr. Steven Sharfstein, APA Vice President told Congress. The money is in prescription psychiatric drugs as demonstrated by the astounding fact that in 2007 the five leading psychiatric drugs grossed more money than the gross national product of half the countries in the world.

The French philosopher Voltaire wrote, “Those who can make you believe absurdities, can make you commit atrocities.” The conjoined twins of the pharmaceutical industry and psychiatry are doing their best to have the public believe the absurdity that the stress and emotional roller coaster of becoming a new mother is a mental illness. Then they get these vulnerable women to commit the atrocity of taking mind-altering, addictive antidepressant drugs that go directly into the baby through the mother’s milk. These drugs can make a new mother’s life a living hell. Ask Amy Philo.

Even if the mother does not suffer visible side effects from an antidepressant, she is still consuming an addictive drug that is a neurotoxin. And if she breast feeds, her baby is consuming a drug that has been shown to cause severe, irreparable damage.

Pregnant women taking antidepressants have babies who are 6 times more likely to have primary pulmonary hypertension (PPH) or a developing lung disorder. PPH is extremely serious. The drug causes developmental distortion of the lungs leading to lack of oxygen to crucial organs such as the brain, kidneys and liver. PPH is often fatal. Babies who initially survive PPH have long-term health problems including breathing difficulties, seizures and developmental disorders.

K.L. Carlson is a former drug rep turned whistleblower, author of the compelling expose, Diary of a Legal Drug Dealer – One Drug Rep. Dares to Tell You the Truth. She is also a CCHR International Commissioner (advisor)

Read the rest of this  article here:  http://www.opednews.com/articles/PHARMACEUTICAL-S-CONTROL-P-by-K-L-Carlson-100803-846.html

« Return to news items


Share